Top Structural Heart Devices Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Structural Heart Devices Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Structural Heart Devices industry players.

Structural Heart Devices Market Competitive Landscape

The global structural heart devices market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Structural Heart Devices. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions.

Structural Heart Devices Market Top Player’s Company Profiles

  • Boston Scientific Corporation (United States)
  • LivaNova PLC (United Kingdom)
  • MicroPort Scientific Corporation (China)
  • Terumo Corporation (Japan)
  • CryoLife, Inc. (United States)
  • W. L. Gore & Associates, Inc. (United States)
  • Meril Life Sciences Pvt. Ltd. (India)
  • Braile Biomédica (Brazil)
  • JenaValve Technology, Inc. (Germany)
  • Lepu Medical Technology Co., Ltd. (China)
  • Xeltis AG (Switzerland)
  • AtriCure, Inc. (United States)
  • CardiAQ Valve Technologies (United States)
  • Transcatheter Technologies GmbH (Germany)
  • Venus Medtech (Hangzhou) Inc. (China)
  • Colibri Heart Valve, LLC (United States)
  • Comed B.V. (Netherlands)
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Structural Heart Devices Market size was valued at USD 15.5 Billion in 2024 and is poised to grow from USD 17.07 Billion in 2025 to USD 36.85 Billion by 2033, growing at a CAGR of 10.1% during the forecast period (2026–2033).

The competitive environment in the market is characterized by leading medical device manufacturers and new start-up companies specializing in advanced, simple solutions for cardiac surgery. Technological advances, increasing clinical research, and strategic partnerships focused on improving patient outcomes drive the growth of this market. Companies are actively pursuing FDA approvals and expanding their services to remain competitive. Key players are investing heavily in research and development, with a strong focus on expanding product offerings and gaining first-hand advantages in new cardiac device technologies. 'Boston Scientific Corporation ', 'Medtronic ', 'Edwards Lifesciences Corporation ', 'Abbott Laboratories ', 'St. Jude Medical ', 'Biomerics ', 'Comed BV ', 'LivaNova PLC ', 'JenaValve Technology, Inc. ', 'CardioKinetix ', 'Lepu Medical Technology ', 'CryoLife ', 'Micro Interventional Devices ', 'Braile Biomédica ', 'TTK Healthcare (A TTK Group Company)'

The incidence of heart failure is increasing worldwide due to factors such as aging population, sedentary lifestyle, and poor diet, leading to an increasing demand for cardiac devices, with frequent diagnosis of organized heart failure, such as aortic stenosis, mitral regurgitation, and congenital heart defects in older adults. Advanced cardiac mechanical engineering requirements are likely to perpetuate, with transcatheter intracardiac including veins and occluders. 

Increasing Adoption of Transcatheter Aortic Valve Replacement (TAVR) Systems: Transcatheter aortic valve replacement (TAVR) has become popular as the treatment of choice for patients with severe aortic stenosis, especially those unsuitable for open heart surgery. In clinical trials and ongoing safety studies with the advantages of TAVR, this less penetrating approach continues to increase the demand for structural heart devices will be expected as manufacturers are investing aggressively in next-generation TAVR systems, to expand patients to increase structural heart devices market outlook. 

North America dominated the structural heart devices industry and held the largest revenue share of 40.8% in 2022, due to rising healthcare expenditures, increasing R&D activities, and increasing incidence of heart disease due to growth so in geriatrics. The demand for minimally invasive procedures is also a major reason the region dominates. According to data released by Cedars-Sinai in January 2022, the most common heart surgery is coronary artery bypass graft surgery (CABG)/coronary artery bypass surgery Each year, more than 300,000 patients in the United States undergo surgery prominent. This explains the increasing prevalence of heart disease in the country. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Cardiovascular Devices Market
Buy Now GET FREE SAMPLE
Cardiac Implants Market
Buy Now GET FREE SAMPLE
Heart Pump Device Market
Buy Now GET FREE SAMPLE
Cardiac Assist Devices Market
Buy Now GET FREE SAMPLE
Interventional Cardiology Devices Market
Buy Now GET FREE SAMPLE
Cardiac Rhythm Management Devices Market
Buy Now GET FREE SAMPLE
Wearable Medical Devices Market
Buy Now GET FREE SAMPLE
Neurovascular Devices Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Structural Heart Devices Market
Structural Heart Devices Market

Report ID: SQMIG35G2184

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE